Dyne Therapeutics, Inc DYN

US Biotechnology

$25.18 ▼ -2.14% ($-0.55)

Open $25.80

Prev Close $25.73

Day Range $24.41 – $25.99

52W Range $9.32 – $26.26

Market Cap $4.70B

Beta 1.10

EPS (TTM) $-3.22

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-09-17
Shares Out.	186,750,000
Website	dyne-tx.com/ ↗
Phone	18009279800
Employees	258
Net Income	-$178.6M
Free Cash Flow	-$499.2M
Total Assets	$994.0M
Total Liabilities	$291.9M
Equity	$702.2M

About Dyne Therapeutics, Inc

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Dyne Therapeutics, Inc is a publicly traded company under the ticker symbol DYN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.